

## INVITED REVIEW

**Diagnosis, pathophysiology, management and future issues of trigeminal surgical nerve injuries**T. Renton<sup>1</sup>  & F. Van der Cruyssen<sup>2,3</sup> <sup>1</sup>Department of Oral Surgery, Kings College London, Dental Hospital, Kings College Hospital Trust, London, UK<sup>2</sup>Department of Oral & Maxillofacial Surgery, University Hospitals Leuven, Leuven, Belgium<sup>3</sup>OMFS-IMPACT Research Group, Department of Imaging and Pathology, Faculty of Medicine, University Leuven, Leuven, Belgium**Key words:**

chronic postsurgical pain, neuropathic pain, painful post-traumatic trigeminal neuropathy, post-traumatic trigeminal neuropathic pain, trigeminal nerve injury

**Correspondence to:**T Renton  
Department Oral Surgery  
Kings College London  
4th Floor  
Dental Hospital  
Kings College Hospital Trust  
Denmark Hill  
London SE5 9RS  
UK  
Tel.: +442932994255  
Fax: +442032991210  
email: tara.renton@kcl.ac.uk**Accepted:** 15 November 2019

doi:10.1111/ors.12465

**Abstract**

The trigeminal nerve constitutes the largest sensory cortex representation in the brain compared with other sensory nerves. This is likely due to the fact that the trigeminal nerve underpins our very existence, as it sensorially protects, our five senses including the organs that provide sight, smell, taste, hearing, speech and meninges protecting our brain. Thus, when trigeminal nerve injuries occur, which in the main are preventable and painful, the majority of patients experience mixed symptoms including altered sensation, numbness and ongoing or elicited neuropathic pain. These neuropathic features cause significant impact on the patients' ability to function, for example cold allodynia prevents the patient enjoying cold foods and drinks and undertaking out-door activities or mechanical allodynia frequently interferes with eating, speaking, kissing and sleep. The resultant chronic symptoms and functional impedance result in significant psychological morbidity. Prevention of nerve injuries related to local anaesthesia (LA), endodontics, implants and third molar surgery is imperative as there is no magic bullet to repair these sensory nerve injuries with their related neuropathic pain. Some causes have higher levels of resolution (third molar surgery and LA) some lower levels of resolution (implant surgery and endodontics) and many patient factors will dictate the prevalence of chronic neuropathic pain. The patient must have appropriate consent and their expectations managed with understanding the potential benefits and risks for their chosen interventions. The authors have aimed to provide an up to date evidence base for diagnosis and management of trigeminal nerve injuries.

**Background**

Trigeminal nerve injury (TNI) and subsequent post-traumatic trigeminal neuropathic pain (PTNP), is a problematic consequence of dental or oromaxillofacial surgical procedures with major medico-legal implications.<sup>1</sup> The incidence of lingual nerve injury has remained static in the UK over the last 30 years, but is increasing in the US, as is the incidence of inferior alveolar nerve (IAN) injury in the UK; the latter being due to implant surgery and endodontic therapy.<sup>2</sup> Trigeminal nerve injuries are generally classified as temporary

but can persist and become permanent (by definition after 3 months). Based upon the limited evidence base, nerve injuries caused by implant and endodontic treatments are mainly painful and permanent.<sup>3</sup> Temporary nerve injuries are more likely related to local anaesthesia (LA) or third molar surgery, with mandibular related surgery patients are advised that the rate of permanent inferior alveolar or lingual nerve injuries occur between 0.1–2% of cases.<sup>4,5</sup> LA nerve injuries have a 75% likelihood of recovery.<sup>6,7</sup>


The fifth cranial nerve divisions two and three are the most commonly damaged, caused by implants,

endodontics and third molar surgery (or other high-risk extractions).<sup>8</sup> Nerve damage from surgery can cause chronic postsurgical pain, however, PTNP and chronic postsurgical pain appears to be limited in dentistry and maxillofacial surgery (3–5%)<sup>9–11</sup>, likely as a result of local anaesthetic (LA) infiltration injections preventing peripheral and central sensitisation (Fig. 1). However, the true incidence of trigeminal nerve injuries is not known due to the fact that many procedures occur in private practices and incidents are underreported. Other common general surgical procedures cause chronic postsurgical pain in 20–45% of patients after surgical limb amputation, thoracotomy and breast surgery for example.<sup>12,13</sup> Many of these chronic postsurgical pain patients actually experience neuropathic pain.<sup>14,15</sup>

Iatrogenic (caused by surgery or medicine) trigeminal nerve injuries, result in pain in 70% of patients seen seeking treatment in our clinics.<sup>16</sup> The ongoing or evoked pain results in interference with eating, speaking, sleeping, applying makeup, shaving, kissing, tooth brushing and drinking; just about every social interaction we take for granted. As a result, these injuries have a significant negative effect on the patient’s self-image, quality of life and psychology.<sup>16</sup>

### Risk factors

Risk factors for chronic postsurgical pain (not limited to PTNP) are many (Table 1), highlighting, the



#### Peripheral

1. Wallerian degeneration may favour the development of abnormal activity, including neurochemical abnormalities in the contiguous intact root ganglion, with overexpression of transient receptor potential vanilloid receptor 1 (TRPV1), neurotrophic factors such as brain-derived neurotrophic factor (BDNF), and mRNA for nociceptive neurotransmitters such as CGRP; in fibers spared by the lesion.
2. Ectopic discharges in lesioned fibers and their corresponding ganglia. Within sites of axonal demyelination owing to altered distribution of voltage-dependent sodium channels in the demyelinated segments of the membrane.
3. High frequency stimulation of small myelinated fibers (Aδ) generates pain, and a great deal of data favour the implication of large Aβ fibers in touch allodynia and secondary hyperalgesia. In addition, the temporal dynamics of tactile allodynia after nerve section closely follow those of ectopic discharges in myelinated A fibers, while such discharges are not observed in non myelinated C axons
4. Abnormal activity in axons undamaged by the lesion due to newly inserted sodium channels include; Nav 1.7, 1.3, 1.8 and 1.9
5. Alterations in the expression and regulation of intracellular calcium ions and modulatory receptors on primary afferent terminals.
6. Neuroimmune interactions resulting in enhanced and/or altered production of inflammatory signalling molecules.
7. Sensory-sympathetic coupling and other alterations in receptor signalling.

#### Central

**Ectopic neural activity** After a peripheral nerve lesion, spontaneous activity is evident in both injured and neighbouring uninjured nociceptive afferents. Increasing levels of mRNA for voltage-gated sodium channels seem to correlate with ectopic activity, and increased expression of sodium channels in lesioned and intact fibers might lower action potential threshold until ectopic activity takes place. Similar changes within second-order nociceptive neurons are thought to occur after central lesions, leading to central neuropathic pain.

**Central sensitisation** Secondary allodynia and hyperalgesia (ie, evoked pain, in particular dynamic mechanical allodynia) in the area adjacent to the innervation territory of the lesioned nerves requires involvement of the CNS. Central sensitisation might develop as a consequence of ectopic activity in primary nociceptive afferent fibers and structural damage within the CNS itself might not be necessarily involved. Ongoing discharges of peripheral afferent fibers that release excitatory aminoacids and neuropeptides within the dorsal horn of the spinal cord lead to postsynaptic changes of second-order nociceptive neurons, such as phosphorylation of NMDA and AMPA receptors or expression of voltage-gated sodium channels. These changes induce neuronal hyperexcitability that enables low-threshold mechanosensitive Aβ and Aδ afferent fibers to activate second-order nociceptive neurons. This means that normally innocuous tactile stimuli such as light brushing or pricking the skin become painful. Similar mechanisms might take place not only within the spinal cord, but also at supraspinal levels, as has been reported in patients with central pain.

Figure 1 Diagram illustrating the peripheral and central changes after peripheral sensory nerve injury.

**Table 1** Risk factors for chronic postsurgical pain

Preoperative factors
Pain, moderate to severe, lasting more than 1 month
Repeated surgery
Psychological vulnerability (e.g. catastrophising)
Preoperative anxiety
Female gender
Older age
Workers' compensation
Genetic predisposition
Inefficient diffuse noxious inhibitory control (DNIC)—a descending pathway of pain inhibition
Intraoperative factors
Surgical approach with risk of nerve damage
Post-operative factors
High pain experience (severe)
Radiation therapy to area
Neurotoxic chemotherapy
Depression
Psychological vulnerability
Neuroticism anxiety

complexity of predisposition to persistent pain due to sensory nerve injury.<sup>17</sup>

Nerve damage is likely to result from a combination of poor risk assessment, poor technique and late recognition or management of intraoperative and post-operative signs of neuropathy. Risk assessment involves the patient selection, preoperative planning, both clinical and radiographic and suitable treatment protocol and follow up (Table 2 summarises the surgical risk factors associated with trigeminal nerve injuries and how to avoid them). It is important that the clinician is familiar with the nerve injury risk factors, specific for each of the type of invasive procedures. For example, in the case of protrusion through the inferior dental canal (IDC) and resultant direct IAN mechanical injury by implant drill a 'sudden give' or an 'electric shock' type feeling or high level sudden pain, even with working under LA, is reported by most of the patients seen on our clinic with LA, extraction, implant or endodontic related PTNP. This should result in the clinician stopping surgery, not reaching for another LA block injection and reassessing their surgical position (implant or endodontic) with regard the injured nerve. The problem with implant related nerve injuries is that they are entirely avoidable as this is elective surgery, and likely to be permanent and painful for the patient.<sup>16</sup> However, we must state that even in the best hands, a nerve injury can still occur despite the world's best will to avoid it. This is inherent to the surgical specialty.

**Table 2** Surgical risk factors

Dental local anaesthesia (LA)	<ul style="list-style-type: none"> <li>• Block anaesthesia</li> <li>• Lingual nerve &gt; inferior alveolar nerve</li> <li>• Concentration and type of LA agent</li> <li>• Multiple block injections</li> <li>• Severe pain on injection</li> </ul>
Third molar surgery	<ul style="list-style-type: none"> <li>• Increased patient age</li> <li>• Increased duration of surgery</li> <li>• Lingual access surgery</li> <li>• Inexperience of surgeon</li> <li>• Depth of impaction of mandibular wisdom tooth</li> </ul>
Lingual nerve	<ul style="list-style-type: none"> <li>• Proximity to inferior alveolar nerve</li> <li>• And other lingual nerve risk factors above</li> </ul>
Third molar surgery	<ul style="list-style-type: none"> <li>• Proximity of IDC to planned surgical site (mental loop, characteristics of IDC position in various sites of mandible). Safety zone—the recommendation is 2 mm. This may be insufficient considering that most implant drills are 1.5 mm longer than implants</li> <li>• Longer implants &gt;10 mm</li> <li>• Prevention using drill stops, surgical guides, preoperative 3D planning, intra operative radiographs</li> </ul>
Inferior alveolar nerve	<ul style="list-style-type: none"> <li>• Proximity of tooth apex to the IDC</li> <li>• Root and bone defects that allow chemical to leak from root into local bone area</li> </ul>
Dental implants	
Endodontics	

## Pathophysiology

It is pertinent to recognise that the trigeminal neural pathways have important differences compared to the spinal nerves. The proprioceptive trigeminal afferents are the only first neuron fibres to have their cell bodies in the central nervous system (CNS). This not the only basic morphological difference where the fifth cranial nerve differs from other sensory nerves. The nuclei for the TN including motor, sensory and special sensory nuclei, are all embedded in the midbrain and not the spinal system. The trigeminocervical complex converging input from C2 and C3 likely explains the often comorbid head and neck pains or autonomic signs and symptoms seen in chronic trigeminal pain, including PTNP.<sup>18</sup> In addition, these interactions as well as close anatomical relationship between the trigeminal sensory nuclei and other cranial nerves (7th, 8th and 9th) may relate to referred pain and symptoms in these nerve distributions as well. A well-known interconnection between the fifth and seventh cranial nerve is tested by performing the

corneal reflex. Despite structural differences between the trigeminal somatosensory system and other spinal sensory nerves, there are many similarities with the somatosensory system of the rest of the body, for example using a common channel, the Transient Receptor Potential Cation Channel Subfamily M member 8 (TRPM8), for recognising cold sensations.<sup>19</sup> A more in depth comparison of channels and transmitters is not within the scope of this article but we refer the readers to the included references.<sup>19–21</sup>

A normally functioning sensory system depends on the maintenance of equilibrium between the neurons and their environment.<sup>22</sup> Sequence of events after nerve injury are described below.

### Peripheral nervous system

- Changes in the equilibrium, as caused by nerve damage, leading to a cascade of events progressing from the peripheral to the CNS.<sup>23</sup> During this stage, the presence of inflammatory mediators released during the tissue injury and from the recruited immune cells leads to increased sodium and calcium channel currents, which reduce the thresholds of the nociceptors in the peripheral nervous system (PNS).<sup>17</sup> This increased sensitivity at the site of injury is called peripheral sensitisation (primary hyperalgesia and allodynia).<sup>23</sup>
  - After peripheral injury adenosine triphosphate (ATP) signal transduction induces activation of both cell types further contributing in an inflammatory cascade.<sup>24</sup> The vesicular nucleotide transporter regulates ATP release and could be a potential pharmacological target. Another channel, the subunit  $\alpha 2/\delta$ -1 of the L-type channel of the dihydropyridine receptor, has shown to be highly selective for gabapentin and is abundantly present in the trigeminal neurons. Other key molecules in pain transmission are CGRP and nitric oxide that are released after inflammation occurs, causing upregulation of neurokinin 1 (NK1) receptors. This upregulation causes a higher excitability of the trigeminal neurons. The NK1 receptors are also present in the glial cells.
  - Neuropeptides, neurotransmitters and channels
    - Nerve growth factor (NGF) plays a role in neural navigation of axonal growth. NGF is also upregulated in the trigeminal ganglion (TG) and nucleus.<sup>25–27</sup>
    - Calcitonin gene related peptide (CGRP), Substance P and Neuropeptide Y expression in TG cells increases in response to injury.<sup>28</sup>
    - Sodium voltage gated channels related to pain including, Nav 1.8 and 1.9, are linked to severity
- of pain after lingual nerve injuries.<sup>29,30</sup> A study reported changes in the expression pattern of growth associated protein 43 in the IAN region of the TG. An increase in myelination and axon density of regenerated fibres was associated with the overall recovery process.<sup>31</sup>
- Paracrine effects cause simultaneous release of IL-1  $\beta$  that in turn suppresses voltage-gated potassium channels through protein kinase C/G protein-coupled pathways, which ultimately increases the neural excitability. Studies showed the desirable effect of NK1 blockade at the TG to prevent central sensitisation. Eugenol is a potential inhibitor of the voltage-gated potassium, calcium and sodium channels as well as the hyperpolarisation-activated cyclic nucleotide-gated (HCN) channels. The HCN channels have been identified as key factors in mechanical allodynia.<sup>32</sup>
  - An extensive review by Holland reports the morphological structural and electrophysiological post-injury changes after peripheral sensory nerve of the TG in cats.<sup>33</sup> Crush injuries recovered faster with less central disruption than transection injury, chemical nerve injuries were not evaluated. All nerve injuries resulted in lower conduction velocities and sensory impairment. When immediate re-apposition of cut ends is performed no cell death occurred; however, proximal degeneration and distal Wallerian degeneration were seen as well as axonal sprouting. Associated degenerative changes of brainstem nuclei were observed. If neural gaps were needed to be covered, stretching the nerve after release from its connective tissues resulted in better functional results compared to neural grafting.
  - Traumatic injury to a peripheral nerve, at the distal stump of the nerve fibre, causes Wallerian degeneration at the distal ends of the damaged nerve.<sup>34,35</sup> Schwann cells, responsible for providing trophic support to the nerve fibres, begin to degenerate and lose their myelin or encapsulation in cases of unmyelinated nerves.<sup>36</sup>
  - Schwann cells and their recruited immune cells, clear the debris and release (neuro)-trophic factors that facilitate axonal growth.<sup>37</sup>

### Central consequences—trigeminal ganglion and secondary/ tertiary neurons

The understanding of the structural and molecular changes causing central sensitisation is limited.<sup>38</sup>

- Membrane excitability changes with lower resting membrane potentials causing lower thresholds for transduction.

- Reduction of synaptic activity (with reduced release of inhibitory neurotransmitters), number, inhibition by inhibitory interneurons caused by less transmitter synthesis, and vesicular transport and postsynaptic lower receptor sensitivity.
- Descending tracts facilitate further in the release of postsynaptic potentials.
- Sprouting starts enhancing excitatory synapses further.
- Polysynaptic pathways start to form, causing epileptiform activity with burst-like discharges and synchronisation.
- Increased excitability and synaptic plasticity lead to central sensitisation causing hyperalgesia, allodynia, hyperpathia and aftersensations. This process initiates as early as two days after injury or inflammation and increases when the nociceptor input has halted. This altered pain perception and processing has been evaluated in other pain conditions such as fibromyalgia, migraine-type headache, temporomandibular disorders, rheumatoid arthritis and others.
- Neuropeptides. The chronic constriction sensory nerve injury model in rats revealed
  - A decrease in substance P immunoreactivity at 60 days after injury in the spinal dorsal horn bilaterally.
  - Neuropeptides changes were also observed up to 120 days after injury. Decline in GABA-immunoreactive neurons starts at 896 h after injury bilaterally, with recovery normal levels are resumed at 8 weeks.
  - Glutamate decarboxylase immunoreactive cells also decline after injury, in combination with synaptic changes, for example, long-term potentiation (LTP), central sensitisation gradually becomes clinically apparent and reduces the chance for reversal. The electrophysiological pathway starting at the nociceptive fiber projecting to the TG after action potential firing.
  - Excitatory postsynaptic potentials induce presynaptic transmitter release as well as an enhanced postsynaptic transmitter effect: LTP.
- The continued activity post injury may also lead to maladaptive plasticity in the CNS, that is, increase in the synaptic strength leading to easier activation of nociceptors with what were previously subthreshold stimuli and an enhancement of the receptive fields.<sup>39</sup> Therefore, the uninjured area surrounding the site of damage (or even contralateral area in unilateral nerve damage) also becomes sensitised to mechanical inputs.<sup>22,39</sup> This uncoupling of the stimulus intensity

and stimulus location due to the CNS plasticity is called central sensitisation.<sup>39</sup>

## Diagnosis

### Diagnostic criteria

A TNI can be defined as an injury to the trigeminal nervous tissues. After injury has been inflicted, a painful or non-painful trigeminal neuropathy may develop. When pain arises as a consequence of this nerve injury and certain criteria are met (see below), then one may speak of a neuropathic pain. Currently, the International Association for the Study of Pain (IASP) defines neuropathic pain as 'pain caused by a lesion or disease of the somatosensory nervous system.' A grading system to aid in diagnosing neuropathic pain has been proposed as well.<sup>40</sup> The diagnostic criteria for pain due to trigeminal nerve damage, presently termed as painful post-traumatic trigeminal neuropathy (PPTN) in the latest International Classification of Headache Disorders, 3rd edition (ICHD-3)<sup>41</sup> are:

- Facial and/or oral pain in the distribution(s) of one or both trigeminal nerve(s) and fulfilling criterion C
- History of an identifiable traumatic event to the trigeminal nerve(s), with clinically evident positive (hyperalgesia, allodynia) and/or negative (hypoesthesia, hypoalgesia) signs of trigeminal nerve dysfunction
- Evidence of causation demonstrated by both of the following: a. pain is localised to the distribution(s) of the trigeminal nerve(s) affected by the traumatic event, b. pain has developed <6 months after the traumatic event (*up to 6 months to allow for development of neuropathy after chemotherapy and radiation. Many surgical injuries have immediate onset, but it is possible that the pain only comes on after a few days or weeks.*)
- Not better accounted for by another ICHD-3 diagnosis.

These criteria are very similar to newly suggested criteria proposed by an international collaborative group of orofacial pain and headache researchers under the name of International Classification of Orofacial Pain (ICOP) version 1.0 beta (draft for review) 2019. In the ICOP, PPTN has been slightly renamed to PTNP. Both the ICHD-3 and ICOP present diagnostic criteria for PPTN/PTNP, and the criteria B and D from above can be used for non-painful post-traumatic trigeminal neuropathy (nPTN) for patients with trigeminal nerve damage without any

associated neuropathic pain. A recent review has highlighted some limitations in diagnosis of post-surgical neuropathy and pain in the trigeminal system.<sup>42</sup>

### Clinical assessment

When assessing patients with surgically induced nerve injuries we recommend a holistic approach.<sup>43,44</sup> We must treat the patient with the nerve injury not just the nerve injury. Many of these patients have experienced an unexpected traumatic event which demands a thorough history taking and examination including attention for sensory testing and psychological assessment. These elements are necessary both in diagnosis and in the choice of therapy.

Features of iatrogenic TNI worthy of assessment include:

- Focal sensory neuropathy (mostly present). There is almost always an area of sensory deficit (i.e. often with a mixture of pain, numbness and altered sensation). There may be positive (elicited pain = mechanical allodynia or hyperalgesia) or negative signs (numbness = anaesthesia, expanded two-point discrimination, reduced light touch). This is an important diagnostic feature for sensory nerve neuropathy.
- Pain, discomfort, altered sensation, numbness (anaesthesia). Neuropathic pain, a positive sign, commonly presents with mechanical allodynia (pain to a non-noxious stimuli), mechanical hyperalgesia (increased pain to a noxious stimuli) and hyperpathia (continued altered sensation or pain after stimulation ceases). Fifty to seventy percentage of patients report a combination of numbness, altered sensation and pain is experienced, the pain may be either spontaneous ongoing pain, which often had a burning character, and spontaneous shooting, electric shock-like sensations (neuralgia).<sup>16</sup> Evoked pain due to touch (mechanical allodynia) or cold (thermal allodynia) often leads patients to having difficulties with daily function, such as eating, socialising, kissing, speaking, drinking and tooth brushing.<sup>16</sup>

Psychological factors (anxiety, stress, depression, post-traumatic stress disorder and anger) are related to PTNP<sup>45</sup> and as a consequence, the patients are often anxious, tearful due to the psychological repercussions of surgery. The presence of anxiety or depression has been suggested to negatively affect treatment outcomes in other pain conditions.<sup>46</sup> In striving for better outcomes, it is therefore advisable to also pay attention to the

psychological impact. Psychological assessment requires the use of validated questionnaires exploring anxiety, depression, post-traumatic stress disorder, catastrophising and somatisation. These symptoms are often compounded by the lack of appropriate urgent or continued management by the treating clinician and informed consent, which is given by only 30% of patients, most of whom are not specifically warned about potential nerve injury.<sup>16</sup>

### Mechanosensory assessment

The clinical phenotype of somatosensory function in trigeminal nerve damage includes both positive and negative symptoms, which may be associated with spontaneous or evoked pain. Clinical mechanosensory tests are summarised in Figure 2. These clinical mechanosensory tests have been shown to have a high specificity however they have a low sensitivity. Additional quantitative sensory testing (QST) or emerging imaging technologies such as magnetic resonance neurography or multimodal assessments can aid in further diagnostics.<sup>47,48</sup>

The positive symptoms may be represented by, for example, dysesthesias and negative symptoms, for example, numbness.<sup>49,50</sup> These symptoms are more pronounced and clinically detectable when a major nerve branch is involved.<sup>49</sup> In PTNP, the pain is generally of moderate to severe intensity, continuous in nature, lasts for most of the day, and is present on most days.<sup>16,51</sup> Thus the patient generally presents with hyperaesthesia or hypoaesthesia, the latter is generally better tolerated.

### Management

Decision on managing the patient with a nerve injury is based upon the holistic assessment of the patient. The clinician must assess the degree and impact of the nerve injury and the type of patient. Some patients may present with large painful neuropathies but are happy to continue as is with minimal life impact, whereas others may present with small areas of neuropathy with no pain but significant related functional and psychological impact. As with all decisions in life there are benefits and risks with any intervention. No reparative surgery or chronic pain medication is devoid of side effects or potential risks. The patient has to be made aware of the diagnosis, prognosis and possible interventions with associated risks and benefits. This is a long conversation and may need to take place over several consultations.



**Examination protocol for mechanosensory evaluation of the extraoral dermatome of V3. This protocol could also be applied to other dermatomes.**

**Area affected**

Using forceps run over normal to neuropathic area warning the patient that there may be hypersensitivity as well as hyposensitivity.

Map out the area and record pictorially or by photograph using pen marks on patient's face.  
Estimate the % of extra-oral dermatome is affected by the neuropathy.

(yellow dotted lines indicate V3 dermatome and arrows indicate direction of testing from normal to neuropathic area)



**Subjective function**



Using forceps with beaks together firmly tap (minimum 5 times) the patient's hand several times explaining that is 'normal' 10 out of 10 subjective function. Then tap, with the same pressure, over the unaffected side of the face or tongue and repeat the stimulation explaining that should be 10 out of 10.  
Move your forceps away and explain no stimulation at all is 0 out of 10.  
Repeat over neuropathic area that you have already confirmed and ask the patient to report the level of stimulus according to the NRS scale below.

0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20
Hypoaesthesia										Hyperaesthesia										
No stimulus response					Normal function					Worst stimulus intensity imaginable										

This test can be repeated over different domains of the neuropathy (lip vermillion, lip skin and chin skin or over tongue)

**Light touch**


To evaluate light touch thresholds von Frey filaments are highly recommended. If these are not be available, a pledget can be used instead, placing repeated (minimum 5 times) on normal side first then repeated on affected side; ask the patient to report differences. If the patient is experiencing numbness on stimulation, they will have reduced light touch detection thresholds. However, if the patient is suffering from hyperaesthesia and possible allodynia (pain on touch) this test can be very uncomfortable.



**Figure 2** Mechanosensory tests for routine assessment of surgical trigeminal nerve injuries.

**Sharp blunt discrimination**

Using a dental probe sharp and blunt ends, the unaffected side is tested first. A minimum of five stimulations would be used and the number recognized by the patient (if less than 3 out of 5 then the test is negative). Whilst this test can illustrate hypoaesthesia with reduced sharp detection on the affected side, this test can also identify mechanical hyperalgesia (increased pain on sharp stimulation) which is often extremely uncomfortable for the patient. Sharp thresholds can be estimated using specially designed algometers not used in this study.

**Two-point discrimination (TPD)**

Using college forceps with beaks open and closed (both for five stimulations), TPD function can be estimated. Some authors prefer specially designed calipers which can be set to a specific distance. Normal TPD in the V3 dermatome extraorally ranges from 2-4mm on the lip vermilion to 6-8mm on the skin of the chin.



**Figure 2** Continued.

Many nerve injuries require therapeutic management, as surgical treatment is rarely indicated. The management may include: patient reassurance and education, medical, surgical and/or psychological treatments.

Urgent surgical intervention should be recommended for known or highly suspected nerve injury,

and those related to endodontic or implant nerve injury. Later surgical intervention for hypoaesthetic nerve injuries does not return the patient to normality<sup>43,44</sup> and surgery for patients with pain and hyperaesthesia is not appropriate as the pain is not abated and patients are faced with long term antiepileptics or antidepressants for chronic pain.<sup>13</sup>



### **LA, orthognathic, trauma and non-traumatic (chemotherapy, radiation, secondary to systemic disease and neoplastic local disease) nerve injuries**

Evidence base remains limited for managing these nerve injuries, we only know that there is no 'magic bullet' to fix them. A 'sit and wait' approach has to be adopted with reassurance of the patient. Therapeutic management of the symptoms should be initiated based on the clinical presentation.

- Homecheck – If you cause extreme (funny bone) pain during an intervention, for example an injection, root canal treatment, extraction or implant preparation in your patient do follow them up the next day and check they are OK. If the patient reports numbness, altered sensation and or pain, reassure them, acknowledge their complaints without minimising and arrange review.
- Continue to support and reassure your patient and advise them to visit to confirm the presence of neuropathy. If the neuropathy affects most of the dermatome +/- associated with severe neuropathic pain nerve injury must be suspected. Reassure your patient that 75% of these injuries resolve.
- Say sorry as this is not an admission of guilt.
- Initiate medical management (recommended for other peripheral sensory nerve injuries)
  - High dose oral NSAIDs (400–800 mg Ibuprofen PO QDS) for 2 days only. Bandolier Oxford league table summarises the optimal analgesia for post-operative pain and combined ibuprofen and paracetamol have the smallest number needed to be treated.<sup>52</sup>
  - GMP prescription for prednisolone 5-day step-down dose of 50-40-30-20-10 mg PO (not for patients with contraindications for steroids or NSAIDs).
  - Vitamin B complex (Riboflavin 400 mg once daily for maximum of 3 months plus other vit B complex).<sup>53</sup>
- Arrange a review of the patient. All advice is summarised on the Trigeminalnerve.org.uk website.
- Long-term management of patients with non-resolving LA nerve injuries. The reality for these patients is that if they have persistent neuropathic pain, they have to be treated as such with psychological and medical management. Topical local anaesthetic (lidocaine 5%) patches may assist the patient in sleeping and playing sports in cold weather.<sup>54</sup> Psychological interventions play a significant role in managing these patients and recommendations for treatment of trigeminal neuropathic

pain are also well described by Renton and Zakzrewska.<sup>55</sup>

### **Summary of type and timing of management**

Management of third molar related nerve injuries will depend upon the presentation of the patient (pain, functional and psychological implications), duration and cause of the nerve injury (Fig. 3).<sup>45,56</sup> It is recognised that neuropathic pain does not respond to surgical intervention thus prevention and early management are paramount in preventing chronic life-long pain after routine surgery in these patients. Advice is summarised on the Trigeminalnerve.org.uk website.

The patient with the nerve injury must be treated, not the nerve injury in isolation. The neuropathy, pain, numbness or paraesthesia, with associated functional and psychological impact will be the driving force behind the patient seeking treatment.<sup>56</sup> These factors must be assessed and the potential outcomes, good or bad, be discussed and agreed with the patient.

Patients sustaining LA, orthognathic, oncology and trauma related nerve injuries will mainly be managed therapeutically.<sup>57–61</sup>

Overall there is poor evidence to support late surgical intervention for trigeminal nerve injuries.<sup>62,63</sup> Most studies report on repair procedures undertaken too late and early repair is imperative to minimise central irreversible changes and possibly chronic pain. Generally surgical repair of the trigeminal nerves never returns the patient to preoperative neural function, in addition, there is a risk of making a numb patient (without pain) into one with PTNP (with neuropathic pain).<sup>43,44</sup> As with other post-trauma sensory neuropathies it is recognised that immediate repair is optimal,<sup>64,65</sup> however, this rarely is applied to dental nerve injuries with the misconception that we should sit and wait for resolution resulting in long delays before surgical intervention.<sup>66–68</sup> Referral to a skilled microsurgeon is preferably done in time.

Some recent studies have highlighted immediate repair with cadaveric treated human nerve graft successful in managing various sized defects in planned resection of nerves related to benign tumour resection or trauma.<sup>68–70</sup>

Recent reports have also concluded, similar to other surgical sites, that neuropathic pain does not resolve with surgery, this being the main driver for surgical repair.<sup>43,71</sup>

MANAGEMENT OF TRIGEMINAL NERVE INJURIES RELATED TO DENTAL AND OROMAXILLOFACIAL PROCEDURES					
Timeline	During surgery	Post surgery 2 -6 weeks	12 weeks	> 12 weeks	
<b>Psychological intervention</b>					
<b>Medical intervention</b>					
High risk nerve injury or patient with high risk of developing neuropathic pain: consider pre-emptive amitriptyline or pregabalin		Reported neuropathy immediate post-surgery <ul style="list-style-type: none"> <li>• NSAIDs ibuprofen 6—mg TDS 5 days (MH permitting)</li> <li>• step down prednisolone 50-10 mg over 5 days (exclude known risk of DU and or PU)</li> <li>• Vitamin B complex (long term during recovery)</li> </ul>		If required: psychological support (for PTSD and sleep disorders) and therapeutic management of neuropathic pain (NICE Guidance Neuropathic Pain in adults) <ul style="list-style-type: none"> <li>• Step 1: amitriptyline or nortriptyline</li> <li>• Step 2: gabapentin or pregabalin</li> <li>• Adjunctive topical agents (lidocaine, capsaicin)</li> </ul>	
<b>Surgical intervention</b>					
Known or suspected nerve Inferior alveolar or lingual injury	Post local anaesthesia or orthognathic surgery or trauma	Post implant or endodontic surgery Patient presents with nerve injury early postoperatively	Post M3M surgery Patient presents with nerve injury early postoperatively	Persistent non-resolving <b>lingual nerve injury</b> after lingual access (lingual retraction +/-lingual split) surgery	Patient presents with persistent non-resolving <b>Inferior alveolar nerve injury</b> or <b>lingual nerve injury</b> after M3M surgery
<b>Duty of candour inform patient immediately</b>	<b>Duty of candour inform patient immediately</b>	Confirm extensive dermatome affected, anaesthesia, +/- paraesthesia, +/- neuropathic pain	Confirm extensive dermatome affected, anaesthesia, +/- paraesthesia, +/- neuropathic pain	Confirm extensive dermatome affected, anaesthesia, +/- paraesthesia, +/- neuropathic pain	Confirm extensive dermatome affected, anaesthesia, +/- paraesthesia, +/- neuropathic pain
<b>Repair nerve immediately Or refer for immediate repair to a specialist centre</b>	<b>Surgery not indicated</b> <b>Medical and psychological therapies</b>	<b>Within 30 hours</b> <b>Remove implant or endodontically treated tooth</b> and reassess patient combined with medical intervention above	<b>Lingual nerve (buccal approach) DPT</b> confirms retained roots CBCT confirms lingual plate defect due to M3M surgery <b>Consider early exploration (IAN via M3M socket) +/- nerve repair dependent upon surgical findings</b>	<b>Consider exploration within 12 weeks +/- nerve repair dependent upon surgical findings</b>	Consider medical and psychological therapeutic measures. <b>N.B Surgical repair DOES NOT IMPROVE neuropathic pain</b>
<b>New developments</b>					
<ul style="list-style-type: none"> <li>• MRI micro neurography may assist in confirmation of damage to IAN and LN (currently available in US, under development in London and Belgium).</li> <li>• Larger IAN defects can be optimally repaired using Axogen cadaveric nerve graft (currently NICE approved for hand surgery in UK)</li> </ul>					

Figure 3 Algorithm for management of trigeminal nerve injuries related to dental and oromaxillofacial procedures.

Many reports have recommended the use of conduits (venous, prosthetic), sural nerve grafts and other techniques without sufficient evidence and many with poor outcomes including neuropathy and pain from the donor sites.<sup>72</sup> The future may prove that nerve growth factors, other growth promoting chemical, anti neuropathic pain agents and specialised conduits may play a role in improving repair of trigeminal nerve injuries. The overall conclusions from reviews in this area, is that we have a lot of evidence base to harness. The singular consensus is that prevention of these nerve injuries is possible and optimal.

The timing of intervention and mechanism of injury are paramount in decision making in treatment of trigeminal nerve injuries (summarised in Fig. 3).

1. Counselling is the most useful effective tool for managing patients with problematic permanent sensory nerve injuries.

2. Medical intervention is indicated for patients with pain or discomfort or with anxiety and or depression in relation with chronic pain.<sup>73</sup> However, due to the multiple noxious side effects of chronic pain medication, <18% of patients remain adherent with medication

- Acute (medical)
- Late (chronic pain management with psychological interventions)

3. Surgical intervention is indicated for:

- Immediate surgical repair for suspected or known nerve injury or intended surgical defect after removal of benign tumour or recent trauma.<sup>60</sup>
- Immediate removal of the implant after an implant related injury with post-operative neuropathy with or without neuropathic pain.<sup>59,74</sup>
- Explorative surgery within 36 h if related to development of neuropathy after overfill of root canal-treated tooth.<sup>75-77</sup>

- Within 2–4 weeks if clinical presentation of persistent neuropathy is paramount. Radiographic follow-up is not necessary however if there is cone beam computed tomography (CBCT) evidence of breach of lingual plate or IDC consider immediate action: nerve exploration+/- repair;
  - Lingual nerve neuropathy patients with CBCT evidence of damage to lingual plate adjacent to third molar surgical site.
  - Inferior alveolar nerve with retained roots or evidence of bone inclusions or compression of IDC.
- Within 3 months of injury;
  - Non-resolving lingual or inferior dental nerve injuries. Exploratory surgery for lingual or inferior alveolar nerve injuries within 3 months post injury. Surgical intervention is not effective for neuropathic pain.<sup>43,78</sup> If this is the driving force behind seeking surgery, surgical intervention should be reconsidered.

## Future directions

Exciting results were reported of allografting lingual and IAN injuries. Using a pre-prepared human treated cadaveric allograft the inferior alveolar and lingual nerve can be repaired with minimal tension. This is undertaken using microscopy and described in several publications by John Zuniga and Michael Miloro.<sup>66,79,80</sup> This is likely to be the treatment of choice if repair is indicated and direct reanastomosis cannot be undertaken most commonly for the IAN. One of the main issues regarding nerve repair is the early identification of the neuroma relating to the patients' symptoms, and the connectivity of the nerve itself, that is, is the nerve actually functioning. Recent developments with magnetic resonance neurography has availed the surgeon to identify the nerve lesion and neural functionality to facilitate appropriate and earlier nerve repair intervention.<sup>48</sup>

## Conclusions

This article was intended to acknowledge and share some key issues around surgical trigeminal nerve injuries including pathophysiology, diagnosis and management. Unfortunately, many of the suggested treatment options do not 'fix' the patient but aim to manage their symptoms as best as possible, improve function and allow them time to accommodate to these unfortunate events, which is often not very satisfactory.

Some key take home messages include:

- Neuropathic pain as well as altered sensation and numbness is what most patients experience with iatrogenic sensory nerve injury. This has a significant and unpleasant effect on the patient (improve your consent).
- The majority of iatrogenic nerve injuries are avoidable.
- Owing to the significant problems following nerve injury, pre-operative strategies for minimising this risk of nerve damage need to be considered carefully. Peri-operative planning, operative execution and post-operative care needs improving to minimise and hopefully abolish these injuries.
- Several strategies are presented to assist in preventing nerve injuries.
- Inferior alveolar nerve injuries in relation to implant and endodontic dentistry are permanent and 'unfixable' unless treated quickly within 30 h.
- There is a need for a consensus and standardisation of risk assessment and management, a holistic approach in managing the pain, related effect on functionality and psychological implications caused to the patients affected by iatrogenic nerve injury.

## Acknowledgements

We would like to thank Laure Baert for illustrating the figures.

## Conflict of interest

TR and FVC: none to declare.

## References

1. Caissie R, Goulet J, Fortin M, Morielli D. Iatrogenic paresthesia in the third division of the trigeminal nerve: 12 years of clinical experience. *J Can Dent Assoc (Tor)* 2005;71:185–90.
2. Hillerup S. Iatrogenic injury to oral branches of the trigeminal nerve: Records of 449 cases. *Clin Oral Investig* 2007;11:133–42. <https://doi.org/10.1007/s00784-006-0089-5>.
3. Hegedus F, Diecidue RJ. Trigeminal nerve injuries after mandibular implant placement - practical knowledge for clinicians. *Int J Oral Maxillofac Implants* 2006;21:111–6.
4. Cheung LK, Leung YY, Chow LK, Wong MCM, Chan EKK, Fok YH. Incidence of neurosensory deficits and recovery after lower third molar surgery: a prospective clinical study of 4338 cases. *Int J Oral Maxillofac*

- Surg 2010;39:320–6. <https://doi.org/10.1016/j.ijom.2009.11.010>.
5. Renton T, Janjua H, Gallagher JE, Dalgleish M, Yilmaz Z. UK dentists' experience of iatrogenic trigeminal nerve injuries in relation to routine dental procedures: why, when and how often? *Br Dent J* 2013;214:633–42. <https://doi.org/10.1038/sj.bdj.2013.583>.
  6. Ziccardi V, Assael L. Mechanisms of trigeminal nerve injuries. *Atlas Oral Maxillofac Surg Clin North Am* 2001;9:1–11.
  7. Renton T, Adey-Viscuso D, Meechan JG, Yilmaz Z. Trigeminal nerve injuries in relation to the local anaesthesia in mandibular injections. *Br Dent J* 2010;209:E15. <https://doi.org/10.1038/sj.bdj.2010.978>.
  8. Klazen Y, Van der Cruyssen F, Vranckx M, Van Vlierberghe M, Politis C, Renton T *et al.* Iatrogenic trigeminal post-traumatic neuropathy: a retrospective two-year cohort study. *Int J Oral Maxillofac Surg* 2018;47:789–93. <https://doi.org/10.1016/j.ijom.2018.02.004>.
  9. Miloro M. *Trigeminal Injuries Nerve*. Berlin Heidelberg: Springer-Verlag, 2013. <https://doi.org/10.1007/978-3-642-35539-4>
  10. Baad-Hansen L, Benoliel R. Neuropathic orofacial pain: Facts and fiction. *Cephalalgia* 2017;37:670–9. <https://doi.org/10.1177/0333102417706310>.
  11. Nixdorf DR, Moana-Filho EJ, Law AS, McGuire LA, Hodges JS, John MT. Frequency of nonodontogenic pain after endodontic therapy: a systematic review and meta-analysis. *J Endod* 2010;36:1494–8. <https://doi.org/10.1016/j.joen.2010.06.020>.
  12. Kehlet H, Jensen TS, Woolf CJ. Persistent postsurgical pain: risk factors and prevention. *Lancet* 2006;367:1618–25. [https://doi.org/10.1016/S0140-6736\(06\)68700-X](https://doi.org/10.1016/S0140-6736(06)68700-X).
  13. Wildgaard K, Ravn J, Kehlet H. Chronic post-thoracotomy pain: a critical review of pathogenic mechanisms and strategies for prevention. *Eur J Cardiothorac Surg* 2009;36:170–80. <https://doi.org/10.1016/j.ejcts.2009.02.005>.
  14. Schug SA, Bruce J. Risk stratification for the development of chronic postsurgical pain. *Schmerz* 2018;32:471–6. <https://doi.org/10.1007/s00482-018-0332-4>.
  15. Dual C, Ouchchane L, Schoeffler P, Dubray C, Soule-Sonneville S, Decoene C *et al.* Neuropathic aspects of persistent postsurgical pain: a French multicenter survey with a 6-month prospective follow-up. *J Pain* 2014;15:24.e1–24.e20. <https://doi.org/10.1016/j.jpain.2013.08.014>.
  16. Renton T, Yilmaz Z. Profiling of patients presenting with posttraumatic neuropathy of the trigeminal nerve. *J Orofac Pain* 2011;25:333–44.
  17. Reddi D, Curran N. Chronic pain after surgery: pathophysiology, risk factors and prevention. *Postgrad Med J* 2014;90: 222–7; quiz 226. <https://doi.org/10.1136/postgradmedj-2013-132215>.
  18. Bartsch T, Goadsby PJ. The trigeminocervical complex and migraine: current concepts and synthesis. *Curr Pain Headache Rep* 2003;7:371–6. <https://doi.org/10.1007/s11916-003-0036-y>.
  19. Van der Cruyssen F, Politis C. Neurophysiological aspects of the trigeminal sensory system: an update. *Rev Neurosci* 2018;29:115–23. <https://doi.org/10.1515/revneuro-2017-0044>.
  20. Gonzalez-Ramirez R, Chen Y, Liedtke WB, Morales-Lazaro SL. *TRP Channels and Pain In: Emir TLR editor*. Boca Raton, FL, 2018. <https://doi.org/10.4324/9781315152837-8>.
  21. Bista P, Imlach W. Pathological mechanisms and therapeutic targets for trigeminal neuropathic pain. *Medicines* 2019;6:1–16. <https://doi.org/10.1038/s41413-019-0047-x>
  22. Woolf CJ, Mannion RJ. Neuropathic pain: aetiology, symptoms, mechanisms, and management. *Lancet* 1999;353:1959–64. [https://doi.org/10.1016/S0140-6736\(99\)01307-0](https://doi.org/10.1016/S0140-6736(99)01307-0).
  23. Costigan M, Scholz J, Woolf CJ. Neuropathic pain: a maladaptive response of the nervous system to damage. *Annu Rev Neurosci* 2009;32:1–32. <https://doi.org/10.1146/annurev.neuro.051508.135531>.
  24. Goto T, Oh SB, Takeda M, Shinoda M, Sato T, Gunjikake KK *et al.* Recent advances in basic research on the trigeminal ganglion. *J Physiol Sci* 2016;66:381–6. <https://doi.org/10.1007/s12576-016-0448-1>.
  25. Davies AM. NGF synthesis and NGF receptor expression in the embryonic mouse trigeminal system. *J Physiol* 1990;84:100–3.
  26. Mizumura K, Murase S. Role of nerve growth factor in pain. *Handb Exp Pharmacol* 2015;227:57–77. [https://doi.org/10.1007/978-3-662-46450-2\\_4](https://doi.org/10.1007/978-3-662-46450-2_4).
  27. Tessier-Lavigne M, Placzek M. Target attraction: are developing axons guided by chemotropism? *Trends Neurosci* 1991;14:303–10. [https://doi.org/10.1016/0166-2236\(91\)90142-h](https://doi.org/10.1016/0166-2236(91)90142-h).
  28. Goto T, Iwai H, Kuramoto E. Neuropeptides and ATP signaling in the trigeminal ganglion. *Jpn Dent Sci Rev* 2017;53:117–24. <https://doi.org/10.1016/j.jdsr.2017.01.003>.
  29. Bird EV, Christmas CR, Loescher AR, Smith KG, Robinson PP, Black JA *et al.* Correlation of Nav1.8 and Nav1.9 sodium channel expression with neuropathic pain in human subjects with lingual nerve neuromas. *Mol Pain* 2013;9: <https://doi.org/10.1186/1744-8069-9-52>.
  30. Paula Luiz A, Kopach O, Santana-varela S, Wood JN. The role of Na v 1.9 channel in the development

- of neuropathic orofacial pain associated with trigeminal neuralgia. *Mol Pain* 2015;11: <https://doi.org/10.1186/s12990-015-0076-4>.
31. Ceber M, Sener U, Mihmanli A, Kilic U, Topcu B, Karakas M. The relationship between changes in the expression of growth associated protein-43 and functional recovery of the injured inferior alveolar nerve following transection without repair in adult rats. *J Craniomaxillofac Surg* 2015;43:1906–3. <https://doi.org/10.1016/j.jcms.2015.08.018>.
  32. Yeon K-Y, Chung G, Kim YH, Hwang JH, Davies AJ, Park M-K *et al*. Eugenol reverses mechanical allodynia after peripheral nerve injury by inhibiting hyperpolarization-activated cyclic nucleotide-gated (HCN) channels. *Pain* 2011;152:2108–16. <https://doi.org/10.1016/j.pain.2011.05.018>.
  33. Holland GR, Robinson PP, Smith KG, Pehowich E. A quantitative morphological study of the recovery of cat lingual nerves after transection or crushing. *J Anat* 1996;188:289–97.
  34. Stoll G, Jander S, Myers RR. Degeneration and regeneration of the peripheral nervous system: from Augustus Waller's observations to neuroinflammation. *J Peripher Nerv Syst* 2002;7:13–27. <https://doi.org/10.1046/j.1529-8027.2002.02002.x>.
  35. Waller A. Experiments on the section of the glossopharyngeal and hypoglossal nerves of the frog, and observations of the alterations produced thereby in the structure of their primitive fibres. *Edinburgh Med Surg J* 1851;76:369–76.
  36. Lee HK, Shin YK, Jung J, Seo S-Y, Baek S-Y, Park HT. Proteasome inhibition suppresses Schwann cell dedifferentiation in vitro and in vivo. *Glia* 2009;57:1825–34. <https://doi.org/10.1002/glia.20894>.
  37. Gaudet AD, Popovich PG, Ramer MS. Wallerian degeneration: gaining perspective on inflammatory events after peripheral nerve injury. *J Neuroinflammation* 2011;30:110. <https://doi.org/10.1186/1742-2094-8-110>.
  38. Sandkuhler J. Models and mechanisms of hyperalgesia and allodynia. *Physiol Rev* 2009;89:707–58. <https://doi.org/10.1152/physrev.00025.2008>.
  39. Woolf CCJ. Sensitization: implications for the diagnosis and treatment of pain. *Pain* 2011;152(3 Suppl.):S2–S15. <https://doi.org/10.1016/j.pain.2010.09.030>. Central.
  40. Finnerup NB, Haroutounian S, Kamerman P, Baron R, Bennett DLH, Bouhassira D *et al*. Neuropathic pain: an updated grading system for research and clinical practice. *Pain* 2016;157:1599–606. <https://doi.org/10.1097/j.pain.0000000000000492>.
  41. IHS (Headache Classification Committee of the International Headache Society). The International Classification of Headache Disorders, 3rd edition. Cephalgia. 2018. <https://doi.org/10.1177/0333102417738202>.
  42. Devine M, Hirani M, Durham J, Nixdorf DR, Renton T. Identifying criteria for diagnosis of post-traumatic pain and altered sensation of the maxillary and mandibular branches of the trigeminal nerve: a systematic review. *Oral Surg Oral Med Oral Pathol Oral Radiol* 2018; <https://doi.org/10.1016/j.oooo.2017.12.020>.
  43. Zuniga JR, Yates DM, Phillips CL. The presence of neuropathic pain predicts postoperative neuropathic pain following trigeminal nerve repair. *J Oral Maxillofac Surg* 2014;72:2422–7. <https://doi.org/10.1016/j.joms.2014.08.003>.
  44. Leung YY, Cheung LK. Longitudinal treatment outcomes of microsurgical treatment of neurosensory deficit after lower third molar surgery: a prospective case series. *PLoS ONE* 2016;4:e0150149. <https://doi.org/10.1371/journal.pone.0150149>.
  45. Smith JG, Elias L-A, Yilmaz Z, Barker S, Shah K, Shah S *et al*. The psychosocial and affective burden of posttraumatic neuropathy following injuries to the trigeminal nerve. *J Orofac Pain* 2013;27:293–303. <https://doi.org/10.11607/jop.1056>.
  46. Oliveira DS, Vélia Ferreira Mendonça L, Sofia Monteiro Sampaio R, Manuel Pereira Dias de Castro-Lopes J, Ribeiro de Azevedo LF. The impact of anxiety and depression on the outcomes of chronic low back pain multidisciplinary pain management—a multicenter prospective cohort study in pain clinics with one-year follow-up. *Pain Med* 2019;20:736–46. <https://doi.org/10.1093/pm/pny128>.
  47. Teerijoki-Oksa T, Forssell H, Jääskeläinen SK. Validation of diagnostic methods for traumatic sensory neuropathy and neuropathic pain. *Muscle Nerve* 2019;59:342–7. <https://doi.org/10.1002/mus.26400>.
  48. Dessouky R, Xi Y, Zuniga J, Chhabra A. Role of MR neurography for the diagnosis of peripheral trigeminal nerve injuries in patients with prior molar tooth extraction. *Am J Neuroradiol* 2018;39:162–9. <https://doi.org/10.3174/ajnr.A5438>.
  49. Benoliel R, Zadik Y, Eliav E, Sharav Y. Peripheral painful traumatic trigeminal neuropathy: clinical features in 91 cases and proposal of novel diagnostic criteria. *J Orofac Pain* 2012;26:49–58.
  50. Baad-Hansen L, Pigg M, Ivanovic SE, Faris H, List T, Drangsholt M *et al*. Intraoral somatosensory abnormalities in patients with atypical odontalgia - a controlled multicenter quantitative sensory testing study. *Pain* 2013;154:1287–94. <https://doi.org/10.1016/j.pain.2013.04.005>.
  51. Renton T, Yilmaz Z, Gaballah K. Evaluation of trigeminal nerve injuries in relation to third molar surgery in a prospective patient cohort. Recommendations for prevention. *Int J Oral Maxillofac Surg* 2012;41:1509–18. <https://doi.org/10.1016/j.ijom.2012.06.025>.

52. Moore A, McQuay H, Derry S, Moore M. The Oxford League Table of Analgesic Efficacy. Bandolier. Available from: [http://www.bandolier.org.uk/booth/pa\\_inpag/Acutrev/Analgesics/lftab.html](http://www.bandolier.org.uk/booth/pa_inpag/Acutrev/Analgesics/lftab.html)
53. Ang CD, Alviar MJ, Dans AL, Bautista-Velez GG, Villaruz-Sulit MV, Tan JJ *et al.* Vitamin B for treating peripheral neuropathy (Review) Vitamin B for treating peripheral neuropathy. *Cochrane Libr* 2008; 3:3–5. <https://doi.org/10.1002/14651858.CD004573.pub3>. Copyright.
54. Khawaja N, Yilmaz Z, Renton T. Case studies illustrating the management of trigeminal neuropathic pain using topical 5% lidocaine plasters. *Br J pain* 2013;7:107–13. <https://doi.org/10.1177/2049463713483459>.
55. Renton T, Zakrzewska JM. Chapter 22 Orofacial pain. In: Shaw E, Kumar C, Dodds C, editors: *Oxford Textbook of Anaesthesia for Oral and Maxillofacial Surgery*. Oxford University Press, 2010:283–98.
56. Renton T. Minimising and managing nerve injuries in dental surgical procedures. *Fac Dent J* 2011;2:164–71. <https://doi.org/10.1308/204268511X13154691747058>.
57. Ziccardi VB, Zuniga JR. Nerve injuries after third molar removal. *Oral Maxillofac Surg Clin North Am* 2007;19:105–15. <https://doi.org/10.1016/j.coms.2006.11.005>.
58. Greenstein G, Carpentieri JR, Cavallaro J. Nerve damage related to implant dentistry: incidence, diagnosis, and management. *Compend Contin Educ Dent* 2015;36:652–9.
59. Juodzbalys G, Wang H-L, Sabalys G, Sidlauskas A, Galindo-Moreno P. Inferior alveolar nerve injury associated with implant surgery. *Clin Oral Implants Res* 2013;24:183–90. <https://doi.org/10.1111/j.1600-0501.2011.02314.x>.
60. Bede SYH, Ismael WK, Al-Assaf DA, Omer SS. Inferior alveolar nerve injuries associated with mandibular fractures. *J Craniofac Surg* 2012;23:1776–8. <https://doi.org/10.1097/SCS.0b013e318266fda3>.
61. Iannetti G, Fadda TM, Riccardi E, Mitro V, Filiaci F. Our experience in complications of orthognathic surgery: a retrospective study on 3236 patients. *Eur Rev Med Pharmacol Sci* 2013;17:379–84.
62. Kushnerev E, Yates JM. Evidence-based outcomes following inferior alveolar and lingual nerve injury and repair: a systematic review. *J Oral Rehabil* 2015; 42:786–802. <https://doi.org/10.1111/joor.12313>.
63. Coulthard P, Kushnerev E, Yates JM, Walsh T, Patel N, Bailey E *et al.* Interventions for iatrogenic inferior alveolar and lingual nerve injury. *Cochr Database Syst Rev* 2014;CD005293. <https://doi.org/10.1002/14651858.CD005293.pub2>.
64. Susarla SM, Kaban LB, Donoff RB, Dodson TB. Does early repair of lingual nerve injuries improve functional sensory recovery? *J Oral Maxillofac Surg* 2007;65:1070–6. <https://doi.org/10.1016/j.joms.2006.10.010>.
65. Ziccardi VB, Steinberg MJ. Timing of trigeminal nerve microsurgery: a review of the literature. *J Oral Maxillofac Surg* 2007;65:1341–5. <https://doi.org/10.1016/j.joms.2005.11.090>.
66. Zuniga JR. Sensory outcomes after reconstruction of lingual and inferior alveolar nerve discontinuities using processed nerve allograft—a case series. *J Oral Maxillofac Surg* 2015;73:734–44. <https://doi.org/10.1016/j.joms.2014.10.030>.
67. Bagheri SC, Meyer RA, Khan HA, Kuhmichel A, Steed MB. Retrospective review of microsurgical repair of 222 lingual nerve injuries. *J Oral Maxillofac Surg* 2010;68:715–23. <https://doi.org/10.1016/j.joms.2009.09.111>.
68. Strauss ER, Ziccardi VB, Janal MN. Outcome assessment of inferior alveolar nerve microsurgery: a retrospective review. *J Oral Maxillofac Surg* 2006;64:1767–70. <https://doi.org/10.1016/j.joms.2005.11.111>.
69. Salomon D, Miloro M, Kolokythas A. Outcomes of immediate allograft reconstruction of long-span defects of the inferior alveolar nerve. *J Oral Maxillofac Surg* 2016;74:2507–14. <https://doi.org/10.1016/j.joms.2016.05.029>.
70. Yampolsky A, Ziccardi V, Chuang SK. Efficacy of acellular nerve allografts in trigeminal nerve reconstruction. *J Oral Maxillofac Surg* 2017;75:2230–4. <https://doi.org/10.1016/j.joms.2017.02.015>.
71. Zuniga JR, Renton TF. Managing post-traumatic trigeminal neuropathic pain: is surgery enough? *J Neurol Neuromed* 2016;1:10–14.
72. Rebowe R, Rogers A, Yang X, Kundu SC, Smith TL, Li Z *et al.* Nerve repair with nerve conduits: problems, solutions, and future directions. *J Hand Microsurg* 2018;10:61–65. <https://doi.org/10.1055/s-0038-1626687>.
73. Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH *et al.* Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations. *Lancet Neurol* 2015;14:162–73. [https://doi.org/10.1016/S1474-4422\(14\)70251-0](https://doi.org/10.1016/S1474-4422(14)70251-0). Pharmacotherapy.
74. Juodzbalys G, Wang H-L, Sabalys G. Injury of the inferior alveolar nerve during implant placement: a literature review. *J Oral Maxillofac Res* 2011;2:e1. <https://doi.org/10.5037/jomr.2011.2101>.
75. Rosen E. The diagnosis and management of nerve injury during endodontic treatment. *Evidence-based Endod* 2017;2:1–7. <https://doi.org/10.1186/s41121-017-0013-2>.
76. Pogrel MA. Damage to the inferior alveolar nerve as the result of root canal therapy. *J Am Dent Assoc* 2007;138:65–69. <https://doi.org/10.14219/jada.archive.2007.0022>.

77. Rosen E, Goldberger T, Taschieri S, Del Fabbro M, Corbella S, Tsesis I. The prognosis of altered sensation after extrusion of root canal filling materials: a systematic review of the literature. *J Endod* 2016;42:873–9. <https://doi.org/10.1016/j.joen.2016.03.018>.
78. Zuniga JR, Yates DM. Factors determining outcome after trigeminal nerve surgery for neuropathic pain. *J Oral Maxillofac Surg* 2016;74:1323–9. <https://doi.org/10.1016/j.joms.2016.02.005>.
79. Akbari M, Miloro M. The inferior alveolar nerve: to graft or not to graft in ablative mandibular resection? *J Oral Maxillofac Surg* 2019;77:1280–5. <https://doi.org/10.1016/j.joms.2019.01.008>.
80. Miloro M, Ruckman P 3rd, Kolokythas A. Lingual nerve repair: to graft or not to graft? *J Oral Maxillofac Surg* 2015;73:1844–50. <https://doi.org/10.1016/j.joms.2015.03.018>.